Microtubule-associated protein tau facilitates the targeted killing of proliferating cancer cells in vitro and in a xenograft mouse tumour model in vivo

British Journal of Cancer

Volumn 109, Issue 6, 2013, Pages 1570-1578

  Hristodorov, D ^a   Mladenov, R ^a   Pardo, A ^a   Pham, A T ^a   Huhn, M ^a   Fischer, R ^b,c   Thepen, T ^b   Barth, S ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

^c RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSTATIC AGENT; GAMMA UROGASTRONE; RECOMBINANT HUMAN EPIDERMAL GROWTH FACTOR MICROTUBULE ASSOCIATED PROTEIN TAU; TAU PROTEIN; TUBULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER MODEL; CELL ASSAY; CELL PROLIFERATION; CELL VIABILITY; CHROMATOGRAPHY; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG SYNTHESIS; ESCHERICHIA COLI; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEOPLASM; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; EPIDERMAL GROWTH FACTOR; ESCHERICHIA COLI; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; RANDOM ALLOCATION; RECOMBINANT FUSION PROTEINS; TAU PROTEINS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884595175     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.457     Document Type: Article

References (51)

1. Barth S, Huhn M, Matthey B, Klimka A, Galinski EA, Engert A (2000) Compatible-solute-supported periplasmic expression of functional recombinant proteins under stress conditions. Appl Environ Microbiol 66(4): 1572-1579.
2. Billingsley ML, Kincaid RL (1997) Regulated phosphorylation and dephosphorylation of tau protein: Effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem J 323(Pt 3): 577-591.
3. Bruell D, Bruns CJ, Yezhelyev M, Huhn M, Muller J, Ischenko I, Fischer R, Finnern R, Jauch KW, Barth S (2005) Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice. Int J Mol Med 15(2): 305-313.
4. Bruns CJ, Harbison MT, Kuniyasu H, Eue I, Fidler IJ (1999) In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1(1): 50-62.
5. Carter PJ, Senter PD (2008) Antibody-drug conjugates for cancer therapy. Cancer J 14(3): 154-169.
6. Cassimeris L (2002) The oncoprotein 18/stathmin family of microtubule destabilizers. Curr Opin Cell Biol 14(1): 18-24.
7. Cawley DB, Herschman HR, Gilliland DG, Collier RJ (1980) Epidermal growth factor-toxin A chain conjugates: EGF-ricin A is a potent toxin while EGF-diphtheria fragment A is nontoxic. Cell 22(2 Pt 2): 563-570.
8. Dickson DW (2004) Apoptotic mechanisms in Alzheimer neurofibrillary degeneration: Cause or effect? J Clin Invest 114(1): 23-27.
9. Dimitroulis J, Stathopoulos GP (2005) Evolution of non-small cell lung cancer chemotherapy (Review). Oncol Rep 13(5): 923-930.
10. Ducry L, Stump B (2010) Antibody-drug conjugates: Linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem 21(1): 5-13.
11. Feinstein SC, Wilson L (2005) Inability of tau to properly regulate neuronal microtubule dynamics: A loss-of-function mechanism by which tau might mediate neuronal cell death. Biochim Biophys Acta 1739(2-3): 268-279.
12. Giodini A, Kallio MJ, Wall NR, Gorbsky GJ, Tognin S, Marchisio PC, Symons M, Altieri DC (2002) Regulation of microtubule stability and mitotic progression by survivin. Cancer Res 62(9): 2462-2467.
13. Goncalves A, Tredan O, Villanueva C, Dumontet C (2012) [Antibody-drug conjugates in oncology: From the concept to trastuzumab emtansine (T-DM1)]. Bull Cancer 99(12): 1183-1191.
14. Hetzel C, Bachran C, Fischer R, Fuchs H, Barth S, Stocker M (2008) Small cleavable adapters enhance the specific cytotoxicity of a humanized immunotoxin directed against CD64-positive cells. J Immunother 31(4): 370-376.
15. Hristodorov D, Mladenov R, Huhn M, Barth S, Thepen T (2012) Macrophagetargeted therapy: CD64-based immunotoxins for treatment of chronic inflammatory diseases. Toxins (Basel) 4(9): 676-694.
16. Huhn M, Sasse S, Tur MK, Matthey B, Schinkothe T, Rybak SM, Barth S, Engert A (2001) Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. Cancer Res 61(24): 8737-8742.
17. Iovino M, Patani R, Watts C, Chandran S, Spillantini MG (2010) Human stem cell-derived neurons: A system to study human tau function and dysfunction. PLoS One 5(11): E13947.
18. Jho YS, Zhulina EB, Kim MW, Pincus PA (2010) Monte carlo simulations of tau proteins: Effect of phosphorylation. Biophys J 99(8): 2387-2397.
19. Jordan MA, Kamath K (2007) How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets 7(8): 730-742.
20. Jordan MA, Toso RJ, Thrower D, Wilson L (1993) Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 90(20): 9552-9556.
21. Kampmeier F, Niesen J, Koers A, Ribbert M, Brecht A, Fischer R, Kiessling F, Barth S, Thepen T (2010) Rapid optical imaging of EGF receptor expression with a single-chain antibody SNAP-tag fusion protein. Eur J Nucl Med Mol Imaging 37(10): 1926-1934.
22. Kiyota A, Shintani S, Mihara M, Nakahara Y, Ueyama Y, Matsumura T, Tachikawa T, Wong DT (2002) Anti-epidermal growth factor receptor monoclonal antibody 225 upregulates p27(KIP1) and p15(INK4B) and induces G1 arrest in oral squamous carcinoma cell lines. Oncology 63(1): 92-98.
23. Kreitman RJ (2006) Immunotoxins for targeted cancer therapy. AAPS J 8(3): E532-E551.
24. Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, Fitzgerald DJ, Wilson WH, Pastan I (2009) Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 27(18): 2983-2990.
25. Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, Pastan I (2001) Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 345(4): 241-247.
26. Lambert JM (2005) Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol 5(5): 543-549.
27. Li Z, Yu T, Zhao P, Ma J (2005) Immunotoxins and cancer therapy. Cell Mol Immunol 2(2): 106-112.
28. Ligon LA, Shelly SS, Tokito M, Holzbaur EL (2003) The microtubule plus-end proteins EB1 and dynactin have differential effects on microtubule polymerization. Mol Biol Cell 14(4): 1405-1417.
29. Maney T, Wagenbach M, Wordeman L (2001) Molecular dissection of the microtubule depolymerizing activity of mitotic centromere-associated kinesin. J Biol Chem 276(37): 34753-34758.
30. Mathew M, Verma RS (2009) Humanized immunotoxins: A new generation of immunotoxins for targeted cancer therapy. Cancer Sci 100(8): 1359-1365.
31. Morris M, Maeda S, Vossel K, Mucke L (2011) The many faces of tau. Neuron 70(3): 410-426.
32. Norris B, Pritchard KI, James K, Myles J, Bennett K, Marlin S, Skillings J, Findlay B, Vandenberg T, Goss P, Latreille J, Rudinskas L, Lofters W, Trudeau M, Osoba D, Rodgers A (2000) Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol 18(12): 2385-2394.
33. Ogata M, Chaudhary VK, Pastan I, FitzGerald DJ (1990) Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol. J Biol Chem 265(33): 20678-20685.
34. Pajk B, Cufer T, Canney P, Ellis P, Cameron D, Blot E, Vermorken J, Coleman R, Marreaud S, Bogaerts J, Basaran G, Piccart M (2008) Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: Findings from the EORTC 10001 randomized phase II trial. Breast 17(2): 180-185.
35. Pardo A, Stocker M, Kampmeier F, Melmer G, Fischer R, Thepen T, Barth S (2012) In vivo imaging of immunotoxin treatment using Katushkatransfected A-431 cells in a murine xenograft tumour model. Cancer Immunol Immunother 61(10): 1617-1626.
36. Pasquier E, Carre M, Pourroy B, Camoin L, Rebai O, Briand C, Braguer D (2004) Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. Mol Cancer Ther 3(10): 1301-1310.
37. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ (2006) Immunotoxin therapy of cancer. Nat Rev Cancer 6(7): 559-565.
38. Saxton WM, Stemple DL, Leslie RJ, Salmon ED, Zavortink M, McIntosh JR (1984) Tubulin dynamics in cultured mammalian cells. J Cell Biol 99(6): 2175-2186.
39. Schneider A, Biernat J, von Bergen M, Mandelkow E, Mandelkow EM (1999) Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry 38(12): 3549-3558.
40. Sievers EL, Senter PD (2013) Antibody-drug conjugates in cancer therapy. Annu Rev Med 64: 15-29.
41. Stahnke B, Thepen T, Stocker M, Rosinke R, Jost E, Fischer R, Tur MK, Barth S (2008) Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes. Mol Cancer Ther 7(9): 2924-2932.
42. Tanaka M, Kano Y, Akutsu M, Tsunoda S, Izumi T, Yazawa Y, Miyawaki S, Mano H, Furukawa Y (2009) The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro. Anticancer Res 29(11): 4589-4596.
43. Ten Cate B, de Bruyn M, Wei Y, Bremer E, Helfrich W (2010) Targeted elimination of leukemia stem cells; a new therapeutic approach in hematooncology Curr Drug Targets 11 1 95-110
44. Tur MK, Neef I, Jost E, Galm O, Jager G, Stocker M, Ribbert M, Osieka R, Klinge U, Barth S (2009) Targeted restoration of down-regulated DAPK2 tumor suppressor activity induces apoptosis in Hodgkin lymphoma cells. J Immunother 32(5): 431-441.
45. von Minckwitz G, Harder S, Hovelmann S, Jager E, Al-Batran SE, Loibl S, Atmaca A, Cimpoiasu C, Neumann A, Abera A, Knuth A, Kaufmann M, Jager D, Maurer AB, Wels WS (2005) Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Res 7(5): R617-R626.
46. Weiner LM, Surana R, Wang S (2010) Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat Rev Immunol 10(5): 317-327.
47. Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW (1975) A protein factor essential for microtubule assembly. Proc Natl Acad Sci USA 72(5): 1858-1862.
48. Williams DP, Parker K, Bacha P, Bishai W, Borowski M, Genbauffe F, Strom TB, Murphy JR (1987) Diphtheria toxin receptor binding domain substitution with interleukin-2: Genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Eng 1(6): 493-498.
49. Wu AM, Senter PD (2005) Arming antibodies: Prospects and challenges for immunoconjugates. Nat Biotechnol 23(9): 1137-1146.
50. Zhai Y, Kronebusch PJ, Simon PM, Borisy GG (1996) Microtubule dynamics at the G2/M transition: Abrupt breakdown of cytoplasmic microtubules at nuclear envelope breakdown and implications for spindle morphogenesis. J Cell Biol 135(1): 201-214.
51. Zhou J, Giannakakou P (2005) Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents 5(1): 65-71.